Amyloid beta-Peptides; Biomarkers; tau Proteins; Aged; Alzheimer Disease/blood; Amyloid beta-Peptides/blood; Amyloid beta-Peptides/cerebrospinal fluid; Cognitive Dysfunction/blood; Female; Humans; Male; Middle Aged; tau Proteins/blood; tau Proteins/cerebrospinal fluid; Alzheimer Disease; Cognitive Dysfunction; Multidisciplinary
Abstract :
[en] Previous studies have demonstrated increased tau plasma levels in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD. Much less is known whether increased tau plasma levels can already be detected in the pre-MCI stage of subjective cognitive decline (SCD). In the present study we measured tau plasma levels in 111 SCD patients and 134 age- and gender-matched cognitively healthy controls participating in the DZNE (German Center for Neurodegenerative Diseases) longitudinal study on cognition and dementia (DELCODE). Tau plasma levels were measured using ultra-sensitive, single-molecule array (Simoa) technology. We found no significant different tau plasma levels in SCD (3.4 pg/ml) compared with healthy controls (3.6 pg/ml) after controlling for age, gender, and education (p = 0.137). In addition, tau plasma levels did not correlate with Aβ42 (r = 0.073; p = 0.634), tau (r = -0.179; p = 0.240), and p-tau181 (r = -0.208; p = 0.171) cerebrospinal fluid (CSF) levels in a subgroup of 45 SCD patients with available CSF. In conclusion, plasma tau is not increased in SCD patients. In addition, the lack of correlation between tau in plasma and CSF in the examined cohort suggests that tau levels are affected by different factors in both biofluids.
Disciplines :
Neurology
Author, co-author :
Müller, Stephan; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany. stephan.mueller@med.uni-tuebingen.de
Preische, Oliver; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany ; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
Göpfert, Jens C; Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
Yañez, Viviana A Carcamo; Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
Joos, Thomas O; Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
Boecker, Henning; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Düzel, Emrah; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
Falkai, Peter; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Priller, Josef; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Neuropsychiatry, Charité - Universitätsmedizin Berlin & Berlin Institute of Health, Berlin, Germany
Buerger, Katharina; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany ; Institute for Stroke and Dementia Research (ISD), Klinikum der Universität München, Munich, Germany
Catak, Cihan; Institute for Stroke and Dementia Research (ISD), Klinikum der Universität München, Munich, Germany
Janowitz, Daniel; Institute for Stroke and Dementia Research (ISD), Klinikum der Universität München, Munich, Germany
HENEKA, Michael ; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurology, University Hospital Bonn, Bonn, Germany
Brosseron, Frederic; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurology, University Hospital Bonn, Bonn, Germany
Nestor, Peter; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
Peters, Oliver; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Charité - Universitätsmedizin Berlin, Institute of Psychiatry and Psychotherapy, CBF, Berlin, Germany
Menne, Felix; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Charité - Universitätsmedizin Berlin, Institute of Psychiatry and Psychotherapy, CBF, Berlin, Germany
Schipke, Carola G; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Charité - Universitätsmedizin Berlin, Institute of Neuropathology, Berlin, Germany
Schneider, Anja; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department for Neurodegenerative Diseases and Gerontopsychiatry, University Hospital Bonn, Bonn, Germany
Spottke, Annika; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Fließbach, Klaus; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Kilimann, Ingo; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
Teipel, Stefan; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
Wagner, Michael; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Psychiatry, University Hospital Bonn, Bonn, Germany
Wiltfang, Jens ; German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany ; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Goettingen, Germany
Jessen, Frank; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany
Laske, Christoph; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany ; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
Grundke-Iqbal, I. et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences of the United States of America 83, 4913-4917 (1986).
Fodero-Tavoletti, M. T. et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain: a journal of neurology 134, 1089-1100, doi:10.1093/brain/awr038 (2011).
Vandermeeren, M. et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. Journal of neurochemistry 61, 1828-1834 (1993).
Chiu, M. J. et al. Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease. Human brain mapping 35, 3132-3142, doi:10.1002/hbm.22390 (2014).
Mattsson, N. et al. Plasma tau in Alzheimer disease. Neurology 87, 1827-1835, doi:10.1212/wnl.0000000000003246 (2016).
Zetterberg, H. et al. Plasma tau levels in Alzheimer's disease. Alzheimer's research & therapy 5, 9, doi:10.1186/alzrt163 (2013).
Tzen, K. Y. et al. Plasma Abeta but not tau is related to brain PiB retention in early Alzheimer's disease. ACS chemical neuroscience 5, 830-836, doi:10.1021/cn500101j (2014).
Jessen, F. et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Archives of general psychiatry 67, 414-422, doi:10.1001/archgenpsychiatry.2010.30 (2010).
Reisberg, B. & Gauthier, S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease. International psychogeriatrics 20, 1-16, doi:10.1017/s1041610207006412 (2008).
van Oijen, M., de Jong, F. J., Hofman, A., Koudstaal, P. J. & Breteler, M. M. Subjective memory complaints, education, and risk of Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association 3, 92-97, doi:10.1016/j.jalz.2007.01.011 (2007).
Jessen, F. et al. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimer's & dementia: the journal of the Alzheimer's Association 10, 76-83, doi:10.1016/j.jalz.2012.09.017 (2014).
Folstein, M. F., Folstein, S. E. & McHugh, P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research 12, 189-198 (1975).
Morris, J. C. et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology 48, 1508-1510 (1997).
Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412-2414 (1993).
Janelidze, S. et al. CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: better diagnostic markers of Alzheimer disease. Annals of clinical and translational neurology 3, 154-165, doi:10.1002/acn3.274 (2016).
Hulstaert, F. et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52, 1555-1562 (1999).
Duits, F. H. et al. The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean Alzheimer's & dementia: the journal of the Alzheimer's Association 10, 713-723.e712, doi:10.1016/j.jalz.2013.12.023 (2014).
Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nature biotechnology 28, 595-599, doi:10.1038/nbt.1641 (2010).
Buckley, R. F. et al. A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. Journal of molecular neuroscience: MN 60, 354-361, doi:10.1007/s12031-016-0810-z (2016).
